Author name: admin1

Tuesday, October 09, 2007 African countries should follow Thailand’s lead in manufacturing their own affordable medication in the face of U.S. pressure. By Lara Santoro October 9, 2007 In January, the Thai government gave its domestic drug manufacturers carte blanche to effectively copy the formula for Abbot Laboratories’ AIDS drug, Kaletra, and reproduce it in […]

Lipodystrophy Update- PoWeR Health Solutions Newsletter- Issue 1

CCR5 Antagonists (Maraviroc and Vicriviroc) CCR5 antagonists block viral binding to the CCR5 chemokine coreceptor. Several CCR5 antagonists have been tested in clinical trials. In August 2007, maraviroc was approved for use in multidrug-resistant patients with R5-only virus. A phase IIb/III trial of this agent in treatment-experienced patients has been reported.[4,5] A phase IIb/III study

The Georgetown University Health Policy Institute has written A CONSUMER GUIDE FOR GETTING AND KEEPING HEALTH INSURANCE for each state and the District of Columbia — fifty-one in all. These Consumer Guides are available at this web site and will be updated periodically as changes in federal and state policy warrant. https://healthinsuranceinfo.net/ I hear this

The New Wave of HIV Drugs is Here For the first time in 10 years, HIV+ patients will have access to two new HIV drug classes. Patients with ongoing viral replication that have been failing current medicines will have a “second chance” to control their HIV by starting new drugs to which their virus has

Positively Aware July/August 2007You’re Fired!Changing your doctor by Matt Sharp Donald Trump’s irritating voice rang in my ears as I stormed home from one of the most humiliating experiences as a “patient” in my 20 years of receiving HIV care. The details of the situation are not as important as the light bulb that went

I am seeing a very strong trend of allowing pharmaceutical employees to speak to clinician and patient groups about their products in lectures set up by industry. I have attended many CME based and non CME lectures and I can say that I have hardly seen a neutral or unbiased lecture when a pharma employee

Paul Bellman is one of the most concerned doctors in the US on the subject of how to rescue HIV patients who have ran out of options. Here is a manuscript he wrote for patients and medical students on the subject that I highly recommend for all to read: https://salvagetherapies.org/articals/salvageTreatment_ManualDrBellmanAug07.pdf

This study really worries me. Median CD4 cells were in the 400, and half were naive. So these are not sick patients. I wish they had defined what mild cognitive impairment is. I forget faces, names, things to do, sometimes important personal data, etc. At 48 years old, I have the feeling that this is

If you are thinking about obtaining TMC 125 (Etravirine, a new non nucleoside yet to be approved) via Tibotec’s expanded access program (EAP) and you have developed resistance to non nucleosides in the past (Sustiva, Viramune, Rescriptor), be aware that it is very difficult to know if TMC 125 will work for your virus since

The End of Nandrolone Nelson Vergel, Program for Wellness Restoration https://www.gmhc.org/health/treatment/ti/ti21_1.html The current terrain for wasting patients in the era of HAART On March 20, 2007, Watson Laboratories stopped the production of nandrolone decanoate (old brand name: Deca Durabolin), a low-cost injectable anabolic steroid used for HIV wasting, citing the lack of raw-material suppliers for